ACS DIAGNOSTICS EXPANDS SERVICE TO MONITOR LIFE THREATENING QT PROLONGATION IN COVID-19 PATIENTS

The patented CORE12 device has FDA 510(k) clearance for use with patients requiring measurement, analysis, and reporting of QT Interval. It will help physicians monitor any Covid-19 related medications administered in real time using our integrated cell phone technology. The CORE12 is unique, as it is the only patented 12 lead monitor that can also do up to 30 days of ambulatory real time telemetry. Because of this technology, ACS Diagnostics has the ability to do a standard 12 lead interpretive ECG print out of any portion of any day.

For more information about the Covid-19 monitoring program contact us at info@appliedcardiacsystems.com or visit our website: http://acsd4u.com/